MySheen

After Ancheng Pharmaceutical launched an over-the-counter attack on new drug stocks.

Published: 2024-11-05 Author: mysheen
Last Updated: 2024/11/05, Ancheng International Pharmaceutical Co., Ltd. was listed at 248 yuan per share yesterday, rising 42% to 351 yuan in intraday trading, after it became a new drug stock. Chairman Chen Zhiming said that efforts will be made to repay the support of investors. An Chengyao is the first company to focus on the U.S. Category IV (ParagraphIV) to simplify the marketing process of new drugs.

After Ancheng Pharmaceutical launched an over-the-counter attack on new drug stocks.

安成药业上柜 攻新药股股后

Ancheng International Pharmaceutical Co., Ltd. was listed at 248 yuan per share yesterday, rising 42% to 351 yuan in intraday trading, after it became a new drug stock. Chairman Chen Zhiming said that efforts will be made to repay the support of investors.

An Chengyao is the first Taiwanese pharmaceutical company to focus on category IV (Paragraph IV) simplified new drug marketing procedures (ANDA) and high-tech generic drugs. It has submitted nine ANDA applications to the US Food and Drug Administration (FDA). Products for the treatment of attention deficit hyperactivity disorder have been provisionally approved by FDA (tentative approval).

Chen Zhiguang, general manager of Anchengyao, said it is estimated that two or three products will be sold in the US market next year. In addition to Paragraph IV and high-tech threshold generic drugs, it also actively develops a number of new drugs with market potential through its 100%-owned subsidiary Ancheng Biotech. Ongoing new drug development projects include two small molecular new drugs and one large molecular new drug.

Chen Zhiguang said that in addition to the layout of special scientific name drugs, an Chengyao has spared no effort in new drug development, and among the three new drugs invested, in addition to the AC-301 for the treatment of ocular angiogenesis diseases, the new diabetes drug AC-201 and the new rose spot treatment drug AC-701 have entered the second phase of FDA clinical trials in the United States.

As for the bright performance of the stock price on the first day of the OTC, Chen Zhiming said that he was very glad that the investors supported an Chengyao and would make efforts to repay the investors.

An proprietary medicine's revenue in the first three quarters of this year was 192 million yuan, an annual decrease of 30%, and an after-tax loss of nearly 320 million yuan, or 3.24 yuan per share. With the drugs coming on the market one after another, we will turn losses into profits next year.

 
0